BOSTON--(BUSINESS WIRE)--Jun 12, 2024-- Genialis , the RNA-biomarker company, today announced the appointment of Krista McKerracher as Chairperson of the Board of Directors. McKerracher is a seasoned biopharmaceutical leader passionate about bringing new medicines to patients with life-threatening diseases. Her background includes almost three decades at Johnson & Johnson and Novartis Oncology, where she held senior commercial and senior R&D leadership roles and launched several first-in-class drugs in the hematology/oncology space.
McKerracher rounded out her drug development career at CRISPR Therapeutics, where she led the team that brought the first CRISPR Cas9 ex-vivo gene editing product to the clinic (HbF edited stem cells for hemoglobinopathies.) This press release features multimedia. View the full release here: https://www.
businesswire.com/news/home/20240610583245/en/ Genialis Introduces Krista McKerracher as Chairperson of the Board. Pictured from left to right is the Genialis Board of Directors: Franck Brichory, Debiopharm Innovation Fund (observer); Cédric Odje, Debiopharm Innovation Fund; Krista McKerracher, Fig Advisory; Rafael Rosengarten, PhD, CEO & co-founder, Genialis; Miha Štajdohar, PhD, CTO & co-founder, Genialis; Elia Stupka, PhD, Angelini Ventures; Ita Lu, Taiwania Capital; Paoyen Lai, Taiwania Capital (observer) (Photo: Business Wire) McKerracher joins Cedric Odje, representing Debiopharm Innovation Fund; Ita Lu of Taiwania Capital; independent dir.
